Mirae Asset Global Investments Co. Ltd. Boosts Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

Mirae Asset Global Investments Co. Ltd. increased its holdings in Exact Sciences Co. (NASDAQ:EXASGet Rating) by 19.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 112,740 shares of the medical research company’s stock after purchasing an additional 18,357 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned approximately 0.06% of Exact Sciences worth $7,882,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Exact Sciences by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 15,641,994 shares of the medical research company’s stock worth $1,093,688,000 after purchasing an additional 210,260 shares in the last quarter. ARK Investment Management LLC raised its stake in Exact Sciences by 6.1% in the first quarter. ARK Investment Management LLC now owns 14,323,962 shares of the medical research company’s stock worth $1,001,531,000 after buying an additional 827,948 shares in the last quarter. Capital World Investors lifted its holdings in Exact Sciences by 17.2% in the first quarter. Capital World Investors now owns 5,487,009 shares of the medical research company’s stock worth $383,652,000 after buying an additional 804,159 shares during the period. Spyglass Capital Management LLC boosted its position in Exact Sciences by 18.3% during the 4th quarter. Spyglass Capital Management LLC now owns 2,669,716 shares of the medical research company’s stock valued at $207,784,000 after acquiring an additional 413,713 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Exact Sciences by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 2,171,966 shares of the medical research company’s stock worth $168,782,000 after acquiring an additional 76,790 shares during the period. Institutional investors own 90.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Citigroup lowered their target price on Exact Sciences from $65.00 to $50.00 and set a “neutral” rating for the company in a research note on Wednesday, August 3rd. Cowen dropped their target price on shares of Exact Sciences from $83.00 to $67.00 and set an “outperform” rating on the stock in a report on Wednesday, August 3rd. Credit Suisse Group began coverage on shares of Exact Sciences in a research note on Wednesday, August 24th. They issued an “outperform” rating and a $55.00 price target for the company. Cowen dropped their price objective on shares of Exact Sciences from $83.00 to $67.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 3rd. Finally, Craig Hallum decreased their target price on shares of Exact Sciences from $81.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, August 3rd. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $69.14.

Exact Sciences Stock Performance

EXAS stock opened at $36.30 on Thursday. The stock has a market capitalization of $6.42 billion, a PE ratio of -8.58 and a beta of 1.37. The stock’s 50 day simple moving average is $41.65 and its 200 day simple moving average is $50.65. Exact Sciences Co. has a 12-month low of $34.16 and a 12-month high of $106.27. The company has a current ratio of 2.48, a quick ratio of 2.23 and a debt-to-equity ratio of 0.70.

Insider Activity

In related news, Director Katherine S. Zanotti sold 1,086 shares of Exact Sciences stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $40.13, for a total value of $43,581.18. Following the completion of the sale, the director now directly owns 60,318 shares in the company, valued at approximately $2,420,561.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Exact Sciences news, Director Katherine S. Zanotti sold 4,608 shares of the business’s stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $45.14, for a total transaction of $208,005.12. Following the completion of the sale, the director now directly owns 60,318 shares in the company, valued at approximately $2,722,754.52. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Katherine S. Zanotti sold 1,086 shares of the stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $40.13, for a total value of $43,581.18. Following the transaction, the director now directly owns 60,318 shares in the company, valued at $2,420,561.34. The disclosure for this sale can be found here. Insiders have sold a total of 5,701 shares of company stock valued at $251,872 over the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

Exact Sciences Company Profile

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Read More

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASGet Rating).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.